Diabetic Foot Ulcer Biologics Market to Grow with a CAGR of 5.41% through 2030
Surge in research and development activities is
expected to drive the Global Diabetic Foot Ulcer Biologics Market growth in the
forecast period, 2026-2030.
According to TechSci Research report, “Diabetic
Foot Ulcer Biologics Market - Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global Diabetic
Foot Ulcer Biologics Market stood at USD 0.65 Billion in 2024 and is
anticipated to grow with a CAGR of 5.41% through 2030. Initiatives taken by
government based on diabetic foot ulcer biologics has led to favorable market
conditions for the Global Diabetic Foot Ulcer Biologics Market. Several factors
contribute to the growth of various diabetic foot ulcer biologics products.
As the global diabetes epidemic continues to grow,
particularly in aging populations and developing countries, the incidence of
diabetic foot ulcers is also increasing. This has created a heightened demand
for advanced therapeutic options that can address the complexities of DFUs.
Consequently, pharmaceutical companies, biotechnology firms, and academic
institutions are investing heavily in R&D to develop biologic treatments
that can provide more effective and targeted solutions for diabetic foot
ulcers.
In India, the Drug Controller General of India (DCGI) has granted approval for Phase III clinical trials of innovative DFU treatments. For instance, Adocia's BioChaperone PDGF-BB, a platelet-derived growth factor formulation, received approval to initiate large-scale studies to confirm its efficacy in treating DFUs. This regulatory support facilitates the advancement of promising therapies from the research phase to potential widespread clinical application.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Diabetic Foot Ulcer Biologics Market”
The Global Diabetic Foot Ulcer Biologics Market is
segmented into indication, end user, regional distribution, and company.
Based on Indication, Neuropathic
Diabetic Foot Ulcer have emerged as the dominating segment in the Global Diabetic
Foot Ulcer Biologics Market in 2024. Neuropathic diabetic foot ulcers are the
result of nerve damage caused by diabetes, a condition that affects the sensory
nerves in the feet, leading to a loss of sensation. This increases the risk of
developing foot ulcers, as individuals with diabetic neuropathy may not feel
the initial signs of injury or infection. According to studies, approximately
50% of people with diabetes experience some degree of diabetic neuropathy,
making neuropathic ulcers the most common type of diabetic foot ulcer. As the
global incidence of diabetes continues to rise, the number of patients with
neuropathic ulcers is also increasing, making this segment a dominant force in
the biologics market.
Based on Region, Asia Pacific have emerged as the fastest
growing region in the Global Diabetic Foot Ulcer Biologics Market in 2024. Asia
Pacific is home to some of the highest diabetes prevalence rates in the world,
particularly in countries such as China, India, and Japan. The growing
incidence of diabetes, driven by lifestyle changes, urbanization, and aging
populations, has led to a higher number of patients suffering from diabetic
foot ulcers. As diabetic foot ulcers are a common complication of diabetes, the
demand for advanced biologic treatments to manage and treat these ulcers has
seen a sharp increase, making Asia Pacific a significant growth market for DFU
biologics.
Major companies operating in Global Diabetic Foot
Ulcer Biologics Market are:
- Organogenesis Inc.
- Tissue Regenix Group Plc
- BioTissue Holdings, Inc.
- Integra LifeSciences Holdings Corporation
- MIMEDX Group, Inc.
- Convatec Inc.
- Smith & Nephew PLC
- Stedical Scientific, Inc.
- Zimmer Biomet Holdings, Inc.
- GUNZE LIMITED
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“One of the most promising applications of
nanotechnology in the DFU biologics market is the development of advanced drug
delivery systems. Traditional biologic treatments for diabetic foot ulcers
often face limitations in terms of bioavailability and the ability to target
the wound site effectively. Nanoparticles, such as liposomes, dendrimers, and
nanocarriers, can be engineered to encapsulate active biologic agents like
growth factors and cytokines, allowing for targeted delivery directly to the
wound site. This localized delivery ensures higher therapeutic efficacy,
reduces systemic side effects, and promotes faster wound healing by enhancing
the concentration of therapeutic agents at the site of injury”, said Mr. Karan
Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“Diabetic Foot Ulcer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Neuro-ischemic Ulcers, Neuropathic Diabetic Foot Ulcer, Ischemic Diabetic Foot Ulcer), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Long-Term Care Settings, Others), By Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Diabetic Foot Ulcer Biologics Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Diabetic Foot Ulcer Biologics Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com